METHOD AND SYSTEM FOR DETECTING AND IDENTIFYING DIFFERENT TYPES OF PAIN AND MONITORING SUBSEQUENT THERAPY

• US 20170172495A1
• Filed: 03/18/2015
• Published: 06/22/2017
• Est. Priority Date: 03/18/2014
• Status: Active Application

• Current Assignee: Translational Research Institute Pty Ltd.
• Original Assignee: University of Newcastle
• Inventors: Mountford, Carolyn, Ramadan, Saadallah, Lin, Alexander
• Application Number:
  US15/127,377
• Publication Number:
  US 20170172495A1
• Time in Patent Office: Days
• CPC Class Codes: A61B 5/0042 for the brain
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/4255 Intestines, colon or appendix
• CPC Class Codes: A61B 5/4571 Evaluating the hip
• CPC Class Codes: A61B 5/4824 Touch or pain perception evaluation A61B5/4821 takes precedence
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 5/742 using visual displays A61B5/339 takes precedence
• CPC Class Codes: G01R 33/4633 Sequences for multi-dimensional NMR
• CPC Class Codes: G01R 33/4806 Functional imaging of brain activation

Abstract

The present invention relates to a method and system for using neurochemical markers to identify different types of pain, including chronic and acute, and providing the capacity to monitor response to therapy on an individual basis. The present invention relates to a method and system for using neuro biomarkers to identify pain of different types and origins, and the capacity to monitor response to therapy on a personalized basis.

Claims

1. A method for detecting whether a subject is experiencing pain, comprising:

obtaining MR spectral data from a subject'"'"'s brain tissue using a MR spectroscopy device; and

producing, from the MR spectra obtained, spectral data using 2D COSY which enables the detection of whether the subject is experiencing pain by detecting the presence of at least one marker neurochemical.

2. The method of claim 1, wherein the pain being detected is chronic pain.

3. The method of claim 1, wherein the pain being detected is identified as at least one of neuropathic pain, noicieptive pain, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and IBS.

5. The method of claim 1, wherein the pain being detected is a subcategory of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

6. The method of claim 1, wherein the pain being detected is irritable bowel syndrome (IBS).

7. The method of claim 1, wherein the pain being detected is irritable bowel syndrome (IBS), and further detecting whether the origin of IBS is infectious or non-infectious.

8. The method of claim 1, further including selecting a pain treatment plan based on the type of pain detected, and treating the subject with the selected treatment plan.

9. The method of claim 1, wherein the pain being detected is different to that recorded as a result of a head injury.

10. The method of claim 1, further including the step of treating the subject with a pain medicine, and then detecting whether the pain medicine was effective by repeating the obtaining and producing steps.

11. The method of claim 1, wherein pain is detected by detecting altered neurochemicals.

13. The method of claim 10, wherein the spectral data is obtained and the spectral data is displayed using a magnetic resonance spectroscopy device using a 2D COSY.

14. The method according to claim 10, wherein the spectral data enables a determination of whether the subject has chronic trigeminal neuralgia.

15. The method of claim 10, wherein the spectral data is obtained from a subject'"'"'s brain tissue in vivo.

17. The method of claim 14, wherein the spectral data is obtained and the spectral data is displayed using a magnetic resonance spectroscopy device using a 2D COSY.

18. The method of claim 14, wherein the spectral image enables a determination of whether the subject has chronic trigeminal neuralgia.

19. The method of claim 14, wherein the spectral data is obtained from a subject'"'"'s brain tissue in vivo.

4. (canceled)

12. A method for using neurochemical markers to identify diarrhea-predominant irritable bowel syndrome of infectious from non-infectious origins in a subject, comprising:

obtaining MR spectral data from a subject'"'"'s brain tissue using a MR spectroscopy device; and

producing from the MR spectra a spectral data display having at least one neurochemical marker to enable a determination of whether the subject has irritable bowel syndrome of infectious type, as compared to irritable bowel syndrome of non-infectious type.

16. A method for using neurochemical markers to determine whether a subject having irritable bowel syndrome is of gut-to-brain origin, as compared to of brain-to-gut origin, comprising:

obtaining MR spectral data from a subject'"'"'s brain tissue using a MR spectroscopy device; and

producing from the MR spectra a spectral data display having at least one neurochemical marker to enable a determination of whether the origin of the irritable bowel syndrome is gut-to-brain type, as compared to brain-to-gut type.

20. A system for using neurochemical markers to identify diarrhea-predominant irritable bowel syndrome of infectious from non-infectious origins in a subject, comprising:

a magnetic spectroscopy device for obtaining MR spectral data from a subject'"'"'s brain tissue; and

a display for displaying spectral data having at least one neurochemical marker to enable a determination of whether the subject has irritable bowel syndrome of infectious type, as compared to irritable bowel syndrome of non-infectious type.

21. The system of claim 20, wherein the spectral data is obtained and the spectral data is displayed using a 2D COSY.

22. The system according to claim 20, wherein the spectral image enables a determination of whether the subject has chronic trigeminal neuralgia.

23. The system according to claim 20, wherein the spectral data is obtained from a subject'"'"'s brain tissue in vivo.

24. A system for using neurochemical markers to determine whether a subject having irritable bowel syndrome is of gut-to-brain origin, as compared to of brain-to-gut origin, comprising:

a magnetic spectroscopy device for obtaining MR spectral data from a subject'"'"'s brain tissue; and

a display for displaying spectral data having at least one neurochemical marker to enable a determination of whether the origin of the irritable bowel syndrome is gut-to-brain type, as compared to brain-to-gut type.

25. The system of claim 24, wherein the spectral data is obtained and the spectral data is displayed using a 2D COSY.

26. The system of claim 24, wherein the spectral data enables a determination of whether the subject has chronic trigeminal neuralgia.

27. The system of claim 24, wherein the spectral data is obtained from a subject'"'"'s brain tissue in vivo.

29. The system of claim 26, wherein the pain being detected is chronic pain.

30. The system of claim 26, wherein the pain being detected is at least one of neuropathic and noicieptive pain.

31. The system of claim 26, wherein the pain being detected is chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

32. The system of claim 26, wherein the pain being detected is irritable bowel syndrome (IBS).

33. The system of claim 26, wherein the pain being detected is irritable bowel syndrome (IBS), and whether the origin of IBS is infectious or non-infectious.

34. The system of claim 26, wherein the pain being detected is as a result of a head injury.

28. A system for detecting whether a subject is experiencing pain, comprising:

a magnetic spectroscopy device for obtaining MR spectral data from a subject'"'"'s brain tissue; and

a processor for producing, from the MR spectra obtained, spectral data using 2D COSY which enables the detection of whether the subject is experiencing pain by detecting the presence of at least one marker neurochemical.